Immatics (NASDAQ:IMTX) (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.
At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells. Building on these discoveries, the company’s ACTengine® program engineers autologous T cells with optimized TCRs targeting selected antigens, while the ACTallo® portfolio focuses on off-the-shelf, allogeneic T cell therapies designed for broader patient access. In parallel, Immatics pursues TCR-based bispecific molecules and cancer vaccine candidates to expand its immunotherapy toolbox.
Immatics’ pipeline includes multiple clinical-stage cell therapy candidates, such as IMA201, IMA202 and IMA203, which are being evaluated in a range of solid tumor indications. The company has entered strategic collaborations with leading biopharmaceutical companies to advance certain programs, and it continues to explore partnerships that can accelerate the development and commercialization of its TCR-based assets. These alliances support both late-stage clinical development and global regulatory planning.
Founded in 2000 as a spin-out from the German Cancer Research Center, Immatics maintains its global headquarters in Tübingen, Germany, with a significant R&D presence in Houston, Texas. The company is led by Chief Executive Officer Harpreet Singh and a management team with extensive experience in immuno-oncology, cell therapy and pharmaceutical development. Immatics’ dual-site structure enables close collaboration with academic institutions and biopharma partners across Europe and North America.
